UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 74

Sortiert nach

Bariatric Surgery in Clinical Practice

1, 2022

Link zum Volltext

Verfügbarkeit prüfen

The Potential Role of Digital Health in Obesity Care

Advances in therapy, 2022-10, Vol.39 (10), p.4397-4412

2022

Link zum Volltext

Verfügbarkeit prüfen

Impact of semaglutide on high-sensitivity C-reactive protein: exploratory patient-level analyses of SUSTAIN and PIONEER randomized clinical trials

Cardiovascular diabetology, 2022-09, Vol.21 (1), p.1-172, Article 172

2022

Link zum Volltext

Verfügbarkeit prüfen

Efficacy of Once-Weekly Semaglutide vs Empagliflozin Added to Metformin in Type 2 Diabetes: Patient-Level Meta-analysis

The journal of clinical endocrinology and metabolism, 2020-12, Vol.105 (12), p.1-e4604

2020

Link zum Volltext

Verfügbarkeit prüfen

Impact of baseline characteristics and beta‐cell function on the efficacy and safety of subcutaneous once‐weekly semaglutide: A patient‐level, pooled analysis of the SUSTAIN 1‐5 trials

Diabetes, obesity & metabolism, 2020-03, Vol.22 (3), p.303-314

2020

Link zum Volltext

Verfügbarkeit prüfen

Evaluating the Cost-Effectiveness of Once-Weekly Semaglutide 1 mg Versus Empagliflozin 25 mg for Treatment of Patients with Type 2 Diabetes in the UK Setting

Diabetes therapy, 2021-02, Vol.12 (2), p.537-555

2021

Link zum Volltext

Verfügbarkeit prüfen

Reductions in insulin resistance are mediated primarily via weight loss in subjects with type 2 diabetes on semaglutide

The journal of clinical endocrinology and metabolism, 2019-09, Vol.104 (9), p.4078-4086

2019

Link zum Volltext

Verfügbarkeit prüfen

Recommendations from a Working Group on Obesity Care Competencies for Healthcare Education in the UK: A Report by the Steering Committee

Advances in therapy, 2022-06, Vol.39 (6), p.3019-3030

2022

Link zum Volltext

Verfügbarkeit prüfen

Once-Weekly Semaglutide Reduces HbA1c and Body Weight in Patients with Type 2 Diabetes Regardless of Background Common OAD: a Subgroup Analysis from SUSTAIN 2–4 and 10

Diabetes therapy, 2020-05, Vol.11 (5), p.1061-1075

2020

Link zum Volltext

Verfügbarkeit prüfen

Obesity Treatment in the UK Health System

Current obesity reports, 2016-09, Vol.5 (3), p.320-326

2016

Link zum Volltext

Verfügbarkeit prüfen

SEMAGLUTIDE REDUCES HIGH-SENSITIVITY CRP LEVELS ACROSS DIFFERENT TREATMENT FORMULATIONS: EXPLORATORY ANALYSES OF SUSTAIN 3 AND PIONEER 1, 2 AND 5 TRIALS

Journal of the American College of Cardiology, 2021-05, Vol.77 (18), p.1607-1607

2021

Link zum Volltext

Verfügbarkeit prüfen

Efficacy and Safety of Once-Weekly Semaglutide Versus Exenatide ER in Subjects With Type 2 Diabetes (SUSTAIN 3): A 56-Week, Open-Label, Randomized Clinical Trial

Diabetes care, 2018-02, Vol.41 (2), p.258-266

2018

Link zum Volltext

Verfügbarkeit prüfen

Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes

The New England journal of medicine, 2021-08, Vol.385 (6), p.503-515

2021

Link zum Volltext

Verfügbarkeit prüfen

A Relative Cost of Control Analysis of Once-Weekly Semaglutide Versus Exenatide Extended-Release, Dulaglutide and Liraglutide in the UK

Advances in therapy, 2020-03, Vol.37 (3), p.1248-1259

2020

Link zum Volltext

Verfügbarkeit prüfen

647-P: Efficacy and Safety of GLP-1RAs with or without Baseline SGLT2i: Post-hoc Analysis of the SUSTAIN 10 Trial

Diabetes (New York, N.Y.), 2021-06, Vol.70 (Supplement_1)

2021

Link zum Volltext

Verfügbarkeit prüfen

746-P: Semaglutide Increases the Proportion of People with T2D Achieving a Metabolic Composite Endpoint

Diabetes (New York, N.Y.), 2023-06, Vol.72 (Supplement_1), p.1

2023

Link zum Volltext

Verfügbarkeit prüfen

Physician–patient communication at diagnosis of type 2 diabetes and its links to patient outcomes: New results from the global IntroDia® study

Diabetes research and clinical practice, 2017-05, Vol.127, p.265-274

2017

Link zum Volltext

Verfügbarkeit prüfen

2185-PUB: Once-Weekly Semaglutide 1mg vs. Empagliflozin 25mg as Add-On to Metformin Monotherapy in Patients with Type 2 Diabetes: A Meta-regression Analysis of Individual Patient Data

Diabetes (New York, N.Y.), 2020-06, Vol.69 (Supplement_1)

2020

Link zum Volltext

Verfügbarkeit prüfen

Once-Weekly Semaglutide Reduces HbA 1c and Body Weight in Patients with Type 2 Diabetes Regardless of Background Common OAD: a Subgroup Analysis from SUSTAIN 2-4 and 10

Diabetes therapy, 2020-05, Vol.11 (5), p.1061

2020

Link zum Volltext

Verfügbarkeit prüfen

Once-Weekly Semaglutide Reduces HbA.sub.1c and Body Weight in Patients with Type 2 Diabetes Regardless of Background Common OAD: a Subgroup Analysis from SUSTAIN 2-4 and 10

Diabetes therapy, 2020-03, Vol.11 (5), p.1061

2020

Link zum Volltext

Verfügbarkeit prüfen

Evaluating the Long-Term Cost-Effectiveness of Once-Weekly Semaglutide Versus Once-Daily Liraglutide for the Treatment of Type 2 Diabetes in the UK

Advances in therapy, 2020-05, Vol.37 (5), p.2427-2441

2020

Link zum Volltext

Verfügbarkeit prüfen

Physician–patient communication at prescription of an additional oral drug for type 2 diabetes and its links to patient outcomes – New findings from the global IntroDia® study

Diabetes research and clinical practice, 2019-03, Vol.149, p.89-97

2019

Link zum Volltext

Verfügbarkeit prüfen

Oral Semaglutide Versus Empagliflozin, Sitagliptin and Liraglutide in the UK: Long-Term Cost-Effectiveness Analyses Based on the PIONEER Clinical Trial Programme

Diabetes therapy, 2020-01, Vol.11 (1), p.259-277

2020

Link zum Volltext

Verfügbarkeit prüfen

Physician experiences when discussing the need for additional oral medication with type 2 diabetes patients: Insights from the cross-national IntroDia® study

Diabetes research and clinical practice, 2019-02, Vol.148, p.179-188

2019

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 74

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(30)
Mit Volltextzugriff
(73)

Publikationsform

Sprache

Englisch
(74)
Japanisch
(1)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Bariatric Surgery in Clinical Practice

The Potential Role of Digital Health in Obesity Care

Impact of semaglutide on high-sensitivity C-reactive protein: exploratory patient-level analyses of SUSTAIN and PIONEER randomized clinical trials

Efficacy of Once-Weekly Semaglutide vs Empagliflozin Added to Metformin in Type 2 Diabetes: Patient-Level Meta-analysis

Impact of baseline characteristics and beta‐cell function on the efficacy and safety of subcutaneous once‐weekly semaglutide: A patient‐level, pooled analysis of the SUSTAIN 1‐5 trials

Evaluating the Cost-Effectiveness of Once-Weekly Semaglutide 1 mg Versus Empagliflozin 25 mg for Treatment of Patients with Type 2 Diabetes in the UK Setting

Reductions in insulin resistance are mediated primarily via weight loss in subjects with type 2 diabetes on semaglutide

Recommendations from a Working Group on Obesity Care Competencies for Healthcare Education in the UK: A Report by the Steering Committee

Once-Weekly Semaglutide Reduces HbA1c and Body Weight in Patients with Type 2 Diabetes Regardless of Background Common OAD: a Subgroup Analysis from SUSTAIN 2–4 and 10

Obesity Treatment in the UK Health System

SEMAGLUTIDE REDUCES HIGH-SENSITIVITY CRP LEVELS ACROSS DIFFERENT TREATMENT FORMULATIONS: EXPLORATORY ANALYSES OF SUSTAIN 3 AND PIONEER 1, 2 AND 5 TRIALS

Efficacy and Safety of Once-Weekly Semaglutide Versus Exenatide ER in Subjects With Type 2 Diabetes (SUSTAIN 3): A 56-Week, Open-Label, Randomized Clinical Trial

Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes

A Relative Cost of Control Analysis of Once-Weekly Semaglutide Versus Exenatide Extended-Release, Dulaglutide and Liraglutide in the UK

647-P: Efficacy and Safety of GLP-1RAs with or without Baseline SGLT2i: Post-hoc Analysis of the SUSTAIN 10 Trial

746-P: Semaglutide Increases the Proportion of People with T2D Achieving a Metabolic Composite Endpoint

Physician–patient communication at diagnosis of type 2 diabetes and its links to patient outcomes: New results from the global IntroDia® study

2185-PUB: Once-Weekly Semaglutide 1mg vs. Empagliflozin 25mg as Add-On to Metformin Monotherapy in Patients with Type 2 Diabetes: A Meta-regression Analysis of Individual Patient Data

Once-Weekly Semaglutide Reduces HbA 1c and Body Weight in Patients with Type 2 Diabetes Regardless of Background Common OAD: a Subgroup Analysis from SUSTAIN 2-4 and 10

Once-Weekly Semaglutide Reduces HbA.sub.1c and Body Weight in Patients with Type 2 Diabetes Regardless of Background Common OAD: a Subgroup Analysis from SUSTAIN 2-4 and 10

Evaluating the Long-Term Cost-Effectiveness of Once-Weekly Semaglutide Versus Once-Daily Liraglutide for the Treatment of Type 2 Diabetes in the UK

Physician–patient communication at prescription of an additional oral drug for type 2 diabetes and its links to patient outcomes – New findings from the global IntroDia® study

Oral Semaglutide Versus Empagliflozin, Sitagliptin and Liraglutide in the UK: Long-Term Cost-Effectiveness Analyses Based on the PIONEER Clinical Trial Programme

Thromboprophylactic low-molecular-weight heparin versus standard of care in unvaccinated, at-risk outpatients with COVID-19 (ETHIC): an open-label, multicentre, randomised, controlled, phase 3b trial

Physician experiences when discussing the need for additional oral medication with type 2 diabetes patients: Insights from the cross-national IntroDia® study

Suchergebnisse filtern